Navigation Links
KV Pharmaceutical Company Completes Financial Restatement with the Filing of Fiscal 2007 Form 10-K
Date:3/25/2008

ST. LOUIS, March 25 /PRNewswire-FirstCall/ -- KV Pharmaceutical Company (NYSE: KVA/KVB), a fully integrated specialty pharmaceutical company that develops, manufactures, acquires and markets technology differentiated branded and generic/non-branded prescription pharmaceutical products, announced the filing of its fiscal 2007 Form 10-K with the Securities and Exchange Commission.

The filing includes restatements of previously reported results for fiscal years 1995 through 2006. In addition, the Company filed a Form 10-QA for the quarter ended June 30, 2006 and Form 10-Q's for the quarters ended September 30, 2006 and December 31, 2006. These filings complete the Company's previously announced restatement of financial results. The financial statements for fiscal 2007 included in the Form 10-K filed with the Securities and Exchange Commission are consistent with the previously reported unaudited financial information which was detailed in a press release dated February 15, 2008.

The Company is currently in the process of completing its Form 10-Q's for the fiscal quarters ended June 30, 2007, September 30, 2007 and December 31, 2007. The filing of the fiscal 2007 10-K brings the Company into compliance with the annual reporting conditions for continued trading on the New York Stock Exchange. However, KV will remain on the NYSE late filer list until its fiscal 2008 quarterly filings are completed.

The Company's filings have been delayed due to the previously reported investigation by a Special Committee of independent members of the Board of Directors into the Company's former stock option grant practices. The investigation concluded that no employee, officer or director of the Company engaged in any intentional wrongdoing or was aware that the Company's policies and procedures for granting and accounting for stock options were materially non-compliant with U.S. Generally Accepted Accounting Principles. The investigation also found no intentio
'/>"/>

SOURCE KV Pharmaceutical Company
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine news :

1. AUDIO from Medialink and Solvay Pharmaceuticals: Men with Type 2 Diabetes at Increased Risk for Low Testosterone Should Talk to Their Doctors
2. MAP Pharmaceuticals Appoints H. Ward Wolff to Board of Directors
3. Sales and Marketing Effectiveness in Pharmaceutical Companies Increases Brand Performance
4. Conatus Pharmaceuticals Appoints Anthony W. Fox, MD, Ph.D., as Chief Medical Officer
5. XTL Biopharmaceuticals Announces Financial Results for the Year Ended December 31, 2007
6. Dreier LLP Announces Class Action Lawsuit Against Vertex Pharmaceuticals Incorporated (VRTX)
7. Alseres Pharmaceuticals, Inc. Raises $5 Million
8. Galderma Announces HSR Clearance for Its Proposal to Acquire CollaGenex Pharmaceuticals
9. Transcept Pharmaceuticals to Present at the BioCentury Future Leaders in the Biotech Industry Conference
10. Law Offices of Howard G. Smith Announces Class Action Lawsuit Against Vertex Pharmaceuticals Incorporated
11. Sagent Pharmaceuticals Launches Ciprofloxacin Injection, USP, 5% Dextrose Premix Bag
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2008)...HASSEE, Fla. -- A Florida State University College...s discovered an important new layer of regulation ...greater understanding of the way cancer begins. ,...ces at the College of Medicine, said the findings ...r and could lead to the design of new drugs that k...
(Date:11/21/2008)... Colo., Nov. 21 Heska Co...ll present at the New York Society of,Security An...onference on,December 2, 2008 at 1177 Avenue of t...ntation is scheduled to begin at 9:35 a.m. Eastern...able via live webcast and for two weeks,following...
(Date:11/21/2008)...rchers remain cautious about future antibiotic res..., Nov. 21 (HealthDay News) -- People with moderate...COPD) may be able to reduce the frequency of exace...ntibiotic, a new report says. , The study, pub...rican Journal of Respiratory and Critical Care Med...
(Date:11/21/2008)...Nov. 21 The University... beginning of a collaborative effort to eradicate ...r Breast Cancer Awareness and Research of the Amer...Lady of the United States, and Vivian Fernandez de...ining M. D. Anderson in the initiative are the U.S...
Breaking Medicine News(10 mins):Health News:Long-Term Erythromycin Cut COPD Complications 2Health News:First Lady Laura Bush's Partnership for Breast Cancer Awareness and Research Extends to Panama 2Health News:First Lady Laura Bush's Partnership for Breast Cancer Awareness and Research Extends to Panama 3
...transvaginal ultrasound scans can do away with inv... tests, used for determining// a woman’s success r...Kwee from Vrije Universiteit Medical Center in Ams...e ovaries of women subjects in an IVF program. ...
...re consuming very little of vegetables and fruits ...d other ailments//. This was disclosed by Heidi Bl... Blanck found that 32.6% of the respondents had fr...umed vegetables thrice or more than thrice per day...
...health caused by an unintentional injury or new ch...likely to have difficulty// obtaining recommended ...declines in short-term health, according to a stud...nstitute, Washington, D.C., presented the results ...
...rary of Science) suggests that computers could gue...lating// the wishes of a terminally sick patient. ...tumbled upon this finding while he was analyzing t...ne on the course of action involving a critically ...
Other Medicine News:Health News:Cheaper and Quicker Alternative to Ovarian Reserve Tests 2Health News:Uninsured Often Receive Less Medical Care 2
(Date:11/19/2008)...on Payment from Roche- , , MONTVALE, N.J., ...ticals Corp. (Nasdaq: MEMY ) today announced tha...e 2 trial of R3487/MEM 3454, its lead alpha-7 nico...sociated with schizophrenia (CIAS). The Company h...riggering a $5.0 million payment from its partner ...
(Date:11/18/2008)...v. 18 Forty-two leading...vember national forum to consider cutting-edge inn...nd national economy from outbreaks of dangerous zo..., , Among those innovations: , , , ...tchen table that detects highly contagious and dan...
(Date:11/13/2008)...ests Nutritional Supplements Prior to Surgery, AR...ire/ -- Identifying,malnutrition before surgery in...ing will significantly decrease surgical complicat...ty and boost patient energy levels,according to a...tructive,Surgery(R), the official medical journal ...
(Date:11/12/2008)...o and LOD, Israel, November 12 Sur...r, NY indicated that,patient-specific CTA data can...Mentor(TM), Simbionix US) with high face validity....n improved the operative flow,increased patient s...overall operative and fluoroscopy time and the amo...
Breaking Medicine Technology:Memory Pharmaceuticals Achieves Enrollment Goal for Phase 2 Study of MEM 3454 in Cognitive Impairment Associated With Schizophrenia 2Memory Pharmaceuticals Achieves Enrollment Goal for Phase 2 Study of MEM 3454 in Cognitive Impairment Associated With Schizophrenia 342 Top U.S. Scientists and Specialists Explore Cutting-Edge Innovations to Defend America From Dangerous Zoonotic Diseases 2Plastic Surgeons Warn of Malnutrition in Body Contouring Patients 2Vascular Surgeons Agree: Case Rehearsal Improves Outcomes 2Night Hospitalist Company LLC Launches First Nighttime Hospitalist Telemedicine Solution 22612 1Night Hospitalist Company LLC Launches First Nighttime Hospitalist Telemedicine Solution 22612 2URAC Releases Standards and Measures for Wellness Programs for Public Comment 22608 1URAC Releases Standards and Measures for Wellness Programs for Public Comment 22608 2URAC Releases Standards and Measures for Wellness Programs for Public Comment 22608 3URAC Releases Standards and Measures for Wellness Programs for Public Comment 22608 4URAC Releases Standards and Measures for Wellness Programs for Public Comment 22608 5New Generation Biofuels Set to Join Russell Microcap Index 6178 1New Generation Biofuels Set to Join Russell Microcap Index 6178 2New Generation Biofuels Set to Join Russell Microcap Index 6178 3Pressure BioSciences Inc Announces 24850 000 NIH SBIR Phase II Award for the Development of a New PCT dependent System for Improved Biomarker Disco 2509 1Pressure BioSciences Inc Announces 24850 000 NIH SBIR Phase II Award for the Development of a New PCT dependent System for Improved Biomarker Disco 2509 2Pressure BioSciences Inc Announces 24850 000 NIH SBIR Phase II Award for the Development of a New PCT dependent System for Improved Biomarker Disco 2509 3Pressure BioSciences Inc Announces 24850 000 NIH SBIR Phase II Award for the Development of a New PCT dependent System for Improved Biomarker Disco 2509 4
...sitive Phase IIa Clinical,Trial Results, First cli... Key,Product in AM-Pharma,s Pipeline , BUNNIK, The...pharmaceutical company developing novel therapeuti...today announced the positive,clinical results of i...atients with ulcerative colitis, a chronic and rel...
...nc. (NASDAQ:INSM), a ,biopharmaceutical company fo... the treatment of metabolic diseases with unmet,m...t at this,week,s C.E. Unterberg, Towbin (CEUT) Eme...City. , The conference, to be held at the Manda...m Tuesday, July 10th through Thursday,July 12th. ...
Other Medicine Technology:AM-Pharma Announces Positive Results of Phase IIa Clinical Trial,with Alkaline Phosphatase For Ulcerative Colitis 2AM-Pharma Announces Positive Results of Phase IIa Clinical Trial,with Alkaline Phosphatase For Ulcerative Colitis 3AM-Pharma Announces Positive Results of Phase IIa Clinical Trial,with Alkaline Phosphatase For Ulcerative Colitis 4AM-Pharma Announces Positive Results of Phase IIa Clinical Trial,with Alkaline Phosphatase For Ulcerative Colitis 5Insmed Inc. to Present at C.E. Unterberg, Towbin Growth Conference 2
...erior Chamber Lenses: The Bausch & Lomb PMMA Poste... used for primary implantation for the visual corr...lder where a cataractous lens has been removed by ... intended to be placed in the ciliary sulcus or ca...
Single-Piece PMMA IOLs for the replacement of the human crystalline lens in the visual correction of aphakia.
Multipiece PMMA IOL - Sulcus Fixation.
Single-Piece PMMA IOLs for the replacement of the human crystalline lens in the visual correction of aphakia.
Medicine Products: